These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
251 related articles for article (PubMed ID: 19724914)
1. Triple-negative breast cancers express receptors for luteinizing hormone-releasing hormone (LHRH) and respond to LHRH antagonist cetrorelix with growth inhibition. Buchholz S; Seitz S; Schally AV; Engel JB; Rick FG; Szalontay L; Hohla F; Krishan A; Papadia A; Gaiser T; Brockhoff G; Ortmann O; Diedrich K; Köster F Int J Oncol; 2009 Oct; 35(4):789-96. PubMed ID: 19724914 [TBL] [Abstract][Full Text] [Related]
2. Targeted chemotherapy for triple-negative breast cancers via LHRH receptor. Föst C; Duwe F; Hellriegel M; Schweyer S; Emons G; Gründker C Oncol Rep; 2011 May; 25(5):1481-7. PubMed ID: 21331448 [TBL] [Abstract][Full Text] [Related]
3. Inhibition of growth of ES-2 human ovarian cancers by bombesin antagonist RC-3095, and luteinizing hormone-releasing hormone antagonist Cetrorelix. Chatzistamou I; Schally AV; Szepeshazi K; Groot K; Hebert F; Arencibia JM Cancer Lett; 2001 Sep; 171(1):37-45. PubMed ID: 11485826 [TBL] [Abstract][Full Text] [Related]
4. Luteinizing hormone-releasing hormone agonist triptorelin and antagonist cetrorelix inhibit EGF-induced c-fos expression in human gynecological cancers. Gründker C; Völker P; Schulz KD; Emons G Gynecol Oncol; 2000 Aug; 78(2):194-202. PubMed ID: 10926802 [TBL] [Abstract][Full Text] [Related]
5. Triple negative breast cancers express receptors for LHRH and are potential therapeutic targets for cytotoxic LHRH-analogs, AEZS 108 and AEZS 125. Seitz S; Buchholz S; Schally AV; Weber F; Klinkhammer-Schalke M; Inwald EC; Perez R; Rick FG; Szalontay L; Hohla F; Segerer S; Kwok CW; Ortmann O; Engel JB BMC Cancer; 2014 Nov; 14():847. PubMed ID: 25410881 [TBL] [Abstract][Full Text] [Related]
6. Receptors for luteinizing hormone-releasing hormone (LHRH) in benign prostatic hyperplasia (BPH) as potential molecular targets for therapy with LHRH antagonist cetrorelix. Rozsa B; Nadji M; Schally AV; Dezso B; Flasko T; Toth G; Mile M; Block NL; Halmos G Prostate; 2011 Apr; 71(5):445-52. PubMed ID: 20859992 [TBL] [Abstract][Full Text] [Related]
7. Decrease in the level and mRNA expression of LH-RH and EGF receptors after treatment with LH-RH antagonist cetrorelix in DU-145 prostate tumor xenografts in nude mice. Lamharzi N; Halmos G; Jungwirth A; Schally AV Int J Oncol; 1998 Sep; 13(3):429-35. PubMed ID: 9683774 [TBL] [Abstract][Full Text] [Related]
8. Mechanisms of inhibition of human benign prostatic hyperplasia in vitro by the luteinizing hormone-releasing hormone antagonist cetrorelix. Siejka A; Schally AV; Block NL; Barabutis N BJU Int; 2010 Nov; 106(9):1382-8. PubMed ID: 20151966 [TBL] [Abstract][Full Text] [Related]
9. Effect of long-term treatment with low doses of the LHRH antagonist Cetrorelix on pituitary receptors for LHRH and gonadal axis in male and female rats. Horvath JE; Toller GL; Schally AV; Bajo AM; Groot K Proc Natl Acad Sci U S A; 2004 Apr; 101(14):4996-5001. PubMed ID: 15044692 [TBL] [Abstract][Full Text] [Related]
10. Effects of long-term treatment with the luteinizing hormone-releasing hormone (LHRH) agonist Decapeptyl and the LHRH antagonist Cetrorelix on the levels of pituitary LHRH receptors and their mRNA expression in rats. Horvath JE; Bajo AM; Schally AV; Kovacs M; Herbert F; Groot K Proc Natl Acad Sci U S A; 2002 Nov; 99(23):15048-53. PubMed ID: 12409615 [TBL] [Abstract][Full Text] [Related]
11. Down-regulation and change in subcellular distribution of receptors for luteinizing hormone-releasing hormone in OV-1063 human epithelial ovarian cancers during therapy with LH-RH antagonist Cetrorelix. Halmos G; Schally AV; Kahan Z Int J Oncol; 2000 Aug; 17(2):367-73. PubMed ID: 10891548 [TBL] [Abstract][Full Text] [Related]
12. Agonists and antagonists of GnRH-I and -II reduce metastasis formation by triple-negative human breast cancer cells in vivo. Schubert A; Hawighorst T; Emons G; Gründker C Breast Cancer Res Treat; 2011 Dec; 130(3):783-90. PubMed ID: 21279682 [TBL] [Abstract][Full Text] [Related]
13. Effective treatment of experimental human endometrial cancers with targeted cytotoxic luteinizing hormone-releasing hormone analogues AN-152 and AN-207. Engel JB; Keller G; Schally AV; Nagy A; Chism DD; Halmos G Fertil Steril; 2005 Apr; 83 Suppl 1():1125-33. PubMed ID: 15831285 [TBL] [Abstract][Full Text] [Related]
14. Gonadotropin-releasing hormone (GnRH) agonist leuprolide acetate and GnRH antagonist cetrorelix acetate directly inhibit leiomyoma extracellular matrix production. Britten JL; Malik M; Levy G; Mendoza M; Catherino WH Fertil Steril; 2012 Nov; 98(5):1299-307. PubMed ID: 22901846 [TBL] [Abstract][Full Text] [Related]
15. Effective treatment of experimental ES-2 human ovarian cancers with a cytotoxic analog of luteinizing hormone-releasing hormone AN-207. Arencibia JM; Bajo AM; Schally AV; Krupa M; Chatzistamou I; Nagy A Anticancer Drugs; 2002 Oct; 13(9):949-56. PubMed ID: 12394258 [TBL] [Abstract][Full Text] [Related]
16. Targeted doxorubicin-containing luteinizing hormone-releasing hormone analogue AN-152 inhibits the growth of doxorubicin-resistant MX-1 human breast cancers. Bajo AM; Schally AV; Halmos G; Nagy A Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3742-8. PubMed ID: 14506166 [TBL] [Abstract][Full Text] [Related]
17. Preclinical evaluation of targeted cytotoxic luteinizing hormone-releasing hormone analogue AN-152 in androgen-sensitive and insensitive prostate cancers. Letsch M; Schally AV; Szepeshazi K; Halmos G; Nagy A Clin Cancer Res; 2003 Oct; 9(12):4505-13. PubMed ID: 14555524 [TBL] [Abstract][Full Text] [Related]
18. Changes in subcellular distribution of pituitary receptors for luteinizing hormone-releasing hormone (LH-RH) after treatment with the LH-RH antagonist cetrorelix. Halmos G; Schally AV Proc Natl Acad Sci U S A; 2002 Jan; 99(2):961-5. PubMed ID: 11805337 [TBL] [Abstract][Full Text] [Related]
19. Chronic administration of the luteinizing hormone-releasing hormone (LHRH) antagonist cetrorelix decreases gonadotrope responsiveness and pituitary LHRH receptor messenger ribonucleic acid levels in rats. Pinski J; Lamharzi N; Halmos G; Groot K; Jungwirth A; Vadillo-Buenfil M; Kakar SS; Schally AV Endocrinology; 1996 Aug; 137(8):3430-6. PubMed ID: 8754771 [TBL] [Abstract][Full Text] [Related]
20. Gonadotropin-releasing hormone type II antagonist induces apoptosis in MCF-7 and triple-negative MDA-MB-231 human breast cancer cells in vitro and in vivo. Gründker C; Föst C; Fister S; Nolte N; Günthert AR; Emons G Breast Cancer Res; 2010; 12(4):R49. PubMed ID: 20630060 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]